Clinical trial / 2015
Daily green tea catechins did not reduce one-year prostate cancer rates.
In a randomized, placebo-controlled trial, 97 men with high-grade prostatic intraepithelial neoplasia, atypical small acinar proliferation (ASAP), or both received either 400 mg daily EGCG from green tea catechins or a placebo for one year. One-year prostate cancer incidence did not differ significantly between arms (5 of 49 with catechins vs 9 of 48 with placebo, p = 0.25). The catechin group showed reduced serum PSA (-0.87 ng/mL, 95% CI -1.66 to -0.09).
- Study type
- Randomized controlled trial
- Who was studied
- 97 men with premalignant prostate lesions (HGPIN or ASAP)
- What was measured
- Cumulative 1-year prostate cancer diagnosis rate
THE PAPER
Randomized, Placebo-Controlled Trial of Green Tea Catechins for Prostate Cancer Prevention.
Kumar NB, Pow-Sang J, Egan KM, Spiess PE, Dickinson S, Salup R, Helal M, McLarty J, Williams CR, Schreiber F, Parnes HL, Sebti S, Kazi A, Kang L, Quinn G, Smith T, Yue B, Diaz K, Chornokur G, Crocker T, Schell MJ. Cancer Prev Res (Phila), 2015.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.